English | Nanologica

Nanologica Publishes supplementary Prospectus in Connection with Rights Issue

8 October, 2024

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, SUBJECT TO LEGAL RESTRICTIONS OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES. Nanologica AB (publ) (”Nanologica” or the “Company”) publishes a supplement (the “Supplementary Prospectus”) to the prospectus approved by the Swedish

Nanologica Receives Supplementary Order Worth approximately SEK 1.9 Million from Returning Customer in China

4 October, 2024

Nanologica has received a supplementary order for the company's silica-based purification media NLAB Saga® from the customer in China who at the end of September placed an order for NLAB Saga® at a value of approximately SEK 3.7 million. The value of this supplementary order amounts to approximately SEK 1.9 million. The customer is a pharmaceutical manufacturer that primarily produces peptides including GLP-1 analogues. In June this year, they placed a first order for NLAB

Nanologica Publishes Prospectus in Connection with Rights Issue

26 September, 2024

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, SUBJECT TO LEGAL RESTRICTIONS OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES. Nanologica AB (publ) (”Nanologica” or the “Company”) publishes a prospectus in connection with the rights issue of units corresponding to

Nanologica Receives Order for NLAB Saga® Worth approx. SEK 3,7 Million from Returning Customer in China

26 September, 2024

Nanologica has received an order for the company's silica-based purification media NLAB Saga® from a customer in China. The order is the second order placed by this customer and the value of the new order amounts to approximately SEK 3.7 million. The customer is a pharmaceutical manufacturer that in June this year placed a first order for NLAB Saga® for production, after a period of evaluation of the product. Today's order is thus the second

Bulletin from the Extraordinary General Meeting of Nanologica AB (publ)

23 September, 2024

Today Nanologica AB (publ) held an extraordinary general meeting whereby the following resolutions were adopted. For more detailed information on the content of the resolutions, please see the complete notice of the extraordinary general meeting that is available on the company’s website, www.nanologica.com. Determination of the number of board members, election of a new board member and determination of remunerationThe general meeting resolved to expand the board of directors from five to six members and to

Clarification to the PR Regarding Proposal for Change in the Board of Directors for Nanologica AB (publ)

2 September, 2024

The clarification is that it is the nomination committee of Nanologica AB that has presented the proposal to elect Alexandra Blomberg Montgomery to the board of directors of Nanologica AB. The nomination committee, consisting of Carl-Johan Spak (Flerie Invest AB), Lennart Francke (Swedbank Robur funds), and Kalle Olby (Vega Bianca AB), has in connection with Nanologica AB preparing an Extraordinary General Meeting to be held on 23 September 2024, resolved to propose that the board

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.